MedPath

Adequate Dosage of Sugammadex on Thyroid Surgery

Not Applicable
Completed
Conditions
Thyroid Surgery
Interventions
Registration Number
NCT03689413
Lead Sponsor
Seoul National University Hospital
Brief Summary

This study was designed to compare two dosage of sugammadex after tracheal intubation for optimal condition of continuous intraoperative neuromonitoring in thyroid surgery to protect recurrent laryngeal nerve.

Detailed Description

Vocal cord paralysis is not a rare complication in thyroid surgery. Nerve monitoring technique has been developed, and many clinicians use the technique for saving the concerned nerves. Many studies showed that the effect of sugammadex on reverse of neuromuscular blocking after tracheal intubation. However, optimal dosage was not founded for sugammadex.

This randomized controlled trial is to compare 1 mg/kg and 2 mg/kg as dosage of sugammadex for optimal continuous intraoperative neuromonitoring in thyroid surgery to prevent vocal cord paralysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
102
Inclusion Criteria
  • The patients who need to open thyroid surgery
Exclusion Criteria
  • Who doesn't agree to enroll
  • Who has to receive other drug rather than rocuronium for muscle relaxant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2 mg/kgSugammadex 200 MG in 2 ML InjectionFor '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation. We will use Sugammadex 200 MG in 2 ML Injection for this.
1 mg/kgSugammadex 200 MG in 2 ML InjectionFor '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation. We will use Sugammadex 200 MG in 2 ML Injection for this.
Primary Outcome Measures
NameTimeMethod
Quality of signal of neuromonitoringintraoperative

During operation, surgeon evaluate the quality of signal of neuromonitoring on the basis of NIM III device.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seoul Metropolitan Government Seoul National University Boramae Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath